Gilead Sciences, Inc.'s Kite Pharma, Inc. subsidiary has managed to become the first company with two chimeric antigen receptor T-cell (CAR-T) therapies on the market, but its new Tecartus (brexucabtagene autoleucel, KTE-X19) is almost identical to its first CAR-T therapy, Yescarta (axibabtagene ciloleucel), and Kite is keeping the price tags the same.
Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First
Similar CAR-T Will Carry The Same Cost As Yescarta
As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta.
More from New Products
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.